Startups take up residence in Alderley Park as AstraZeneca exits; Zogenix surges on pain drug progress;

@FierceBiotech: ICYMI: Top 15 highest paid biopharma R&D chiefs. Special report | Follow @FierceBiotech

@JohnCFierce: The turnaround plan: stay put, target drugs, more deals--John Reed sets out on a long-distance run at Roche's pRED. Feature | Follow @JohnCFierce

@DamianFierce: Updated story on Frazier's $377M new fund with comments from General Partner Jamie Topper. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: NIH Feels Multiplying Effects of Government Shutdown. Article from Scientific American | Follow @EmilyMFierce

> Six new startups--including several biotechs--have taken up residence at the new BioHub in Alderley Park. Story

> Zogenix ($ZGNX) shares surged on the news that its troubled pain drug Zohydro may be moving closer to a possible approval. Story

> StemCells ($STEM) has landed regulatory permission to start a study of its stem cell treatment for spinal cord injuries. Report

> KenCord BioTherapeutics may have only $15 million in backing, but it's promising to create 200 new jobs in Charlotte, NC. Story

Medical Device News

@FierceMedDev: Lensar hauls in $87M for laser eye surgery tech. News | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has another great crop of stories for you. Check it out | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Oral peptide delivery biz Enteris lands Nordic partnership. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien CEO: It's about how, not how much, you spend on R&D. Report

> With Mako set for sale, Wright may be next orthopedic M&A target. Story

> Report: French regulators acted too slowly on PIP breast implant scandal. Item

Pharma News

@FiercePharma: Funnily enough, we publish Top 15 Drug Launch Superstars, and 1000s click thru to last year's Top 10 Launch Disasters. | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Acino agrees to $439M takeover offer from private equity firms. More | Follow @CarlyHFierce

> Lilly warns of 'challenging' bid for 2014 sales goal, thanks to yen, emerging markets. News

> Novartis, Sanofi, Biogen tout new MS drug research. Story

Vaccines News

> NIH expands vaccine clinical trial network. Item

> CDC reports across-the-board rises in flu vaccine uptake. Report

> Researchers highlight knowledge gaps hindering cancer vaccines. Story

> Vaccines spared as Merck takes ax to R&D. More

> Government shutdown forces CDC to halt seasonal flu program. Article

Pharma Manufacturing News

@EricPFierce: Hospira faces more vial problems. FDA and co. says glass strands pose potential health threat. More | Follow @EricPFierce

> Ranbaxy denies FDA issues will lead to layoffs. Item

> SCM offers 'blank canvas' to sterile injectable clients. Story

> FDA threatens drugmaker with ban for not paying user fee. Article

> CML, AAIPharma join forces to create CMC specialist. More

And Finally... Investigators at McMasters University say they have developed a novel tuberculosis vaccine. The vaccine relies on a modified cold virus and was developed in the lab of Zhou Xing. Release

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.